Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trial

被引：0
|
作者：
Lennart Tonneijck
Mark M. Smits
Marcel H. A. Muskiet
Trynke Hoekstra
Mark H. H. Kramer
A. H. Jan Danser
Michaela Diamant
Jaap A. Joles
Daniël H. van Raalte
机构：
[1] VU University Medical Center Amsterdam,Department of Internal Medicine/Diabetes Center
[2] VU University Amsterdam,Department of Health Sciences and the EMGO Institute for Health and Care Research
[3] VU University Medical Center,Department of Epidemiology and Biostatistics
[4] Erasmus University Medical Center,Division of Pharmacology and Vascular Medicine, Department of Internal Medicine
[5] University Medical Center,Department of Nephrology and Hypertension
来源：
Diabetologia | 2016年 / 59卷
关键词：
Diabetes; Exenatide; Glomerular filtration rate; Glomerular hyperfiltration; GLP-1 receptor agonist; Glucagon-like peptide-1; Renal function; Renal haemodynamics; Type 2 diabetes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1412 / 1421
页数：9
相关论文
共 50 条
  • [31] The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial
    Juel, Caroline T. B.
    Lund, Asger
    Andersen, Maria M.
    Hansen, Carsten P.
    Storkholm, Jan H.
    Rehfeld, Jens F.
    van Hall, Gerrit
    Hartmann, Bolette
    Albrechtsen, Nicolai J. Wewer
    Holst, Jens J.
    Vilsboll, Tina
    Knop, Filip K.
    DIABETOLOGIA, 2020, 63 (07) : 1285 - 1298
  • [32] The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial
    Caroline T. B. Juel
    Asger Lund
    Maria M. Andersen
    Carsten P. Hansen
    Jan H. Storkholm
    Jens F. Rehfeld
    Gerrit van Hall
    Bolette Hartmann
    Nicolai J. Wewer Albrechtsen
    Jens J. Holst
    Tina Vilsbøll
    Filip K. Knop
    Diabetologia, 2020, 63 : 1285 - 1298
  • [33] Effect of the GLP-1 Receptor Agonist Exenatide on Impaired Awareness of Hypoglycemia in Type 1 Diabetes: A Randomized Controlled Trial
    van Meijel, Lian A.
    Rooijackers, Hanne M.
    Tack, Cees J.
    de Galan, Bastiaan E.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (09): : 4143 - 4150
  • [34] Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomised, double-blind, placebo-controlled study
    Wang, TF
    Pei, D
    Li, JC
    Tsai, WC
    Tsai, CC
    Yao, CY
    Chang, ET
    Hsieh, MC
    Su, KY
    Kuo, SW
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2005, 59 (07) : 746 - 750
  • [35] A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
    Shiina, Akihiro
    Shirayama, Yukihiko
    Niitsu, Tomihisa
    Hashimoto, Tasuku
    Yoshida, Taisuke
    Hasegawa, Tadashi
    Haraguchi, Tadashi
    Kanahara, Nobuhisa
    Shiraishi, Tetsuya
    Fujisaki, Mihisa
    Fukami, Goro
    Nakazato, Michiko
    Iyo, Masaomi
    Hashimoto, Kenji
    ANNALS OF GENERAL PSYCHIATRY, 2010, 9
  • [36] A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
    Akihiro Shiina
    Yukihiko Shirayama
    Tomihisa Niitsu
    Tasuku Hashimoto
    Taisuke Yoshida
    Tadashi Hasegawa
    Tadashi Haraguchi
    Nobuhisa Kanahara
    Tetsuya Shiraishi
    Mihisa Fujisaki
    Goro Fukami
    Michiko Nakazato
    Masaomi Iyo
    Kenji Hashimoto
    Annals of General Psychiatry, 9
  • [37] Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial
    Rosenstock, Julio
    Wysham, Carol
    Frias, Juan P.
    Kaneko, Shizuka
    Lee, Clare J.
    Lando, Laura Fernandez
    Mao, Huzhang
    Cui, Xuewei
    Karanikas, Chrisanthi A.
    Thieu, Vivian T.
    LANCET, 2021, 398 (10295): : 143 - 155
  • [38] LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
    Urva, Shweta
    Coskun, Tamer
    Loh, Mei Teng
    Du, Yu
    Thomas, Melissa K.
    Gurbuz, Sirel
    Haupt, Axel
    Benson, Charles T.
    Hernandez-Illas, Martha
    D'Alessio, David A.
    Milicevic, Zvonko
    LANCET, 2022, 400 (10366): : 1869 - 1881
  • [39] Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)
    Seino, Y.
    Min, K. W.
    Niemoeller, E.
    Takami, A.
    DIABETES OBESITY & METABOLISM, 2012, 14 (10): : 910 - 917
  • [40] Safety and pharmacodynamics of CJC-1134-PC, a novel GLP-1 receptor agonist, in patients with type 2 diabetes mellitus: A randomized, placebo-controlled, double-blind, dose-escalation study
    Wang, Maggie
    Kipnes, Mark
    Matheson, Stephanie
    Wen, Stella
    Lawrence, Betty
    Thibaudeau, Karen
    Castaigne, Jean-Paul
    Ulich, Thomas
    DIABETES, 2007, 56 : A133 - A133
12345